Century-old drug offers new hope for autism treatment
Groundbreaking research has identified a potential new treatment for the core symptoms of autism.
A 100-year old drug improves core features of autism in a double-blind placebo trial
Results released from an N of One: Autism Research Foundation supported small clinical trial in boys with autism may represent one of the most dramatic advances in autism yet. The findings offer both a new view of what autism is and the possibility of the first drug to treat its core symptoms.
The encouraging results from the double-blind, placebo-controlled trial that tested the 100-year-old drug, suramin, were published in the Annals of Clinical and Translational Neurology. In the trial, conducted by Dr. Robert Naviaux at the University of California San Diego School of Medicine, 10 boys ages 5-14 years were given either a single dose of the drug suramin or a placebo. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all 5 boys who were given the active treatments. Those improvements were not seen in any of the children who received a placebo.
Suramin was developed in 1916 to treat African trypanosomiasis, also known as sleeping sickness. It is administered intravenously and is currently only available in hospitals for treating sleeping sickness disease.
The only observed side effects in this study was a temporary mild rash, which disappeared without treatment in 2-3 days. The study used a low dose of suramin, which produced blood levels of 5-15 µM. All previous uses of suramin have been at much higher doses – doses used for sleeping sickness produce blood levels of 50-100 µM for 1-3 months. High doses used for cancer chemotherapy produce blood levels of 150-270 µM for 3-6 months.
In order for this drug to become available to the wider autism community, its effects need to be confirmed and optimal dosage and safety protocols established in bigger studies and tested on large numbers of individuals. The researchers are hoping to start the next phase of their research in 2019.
“On a Saturday about a week after the infusion, his dad was making a snack in the kitchen. My son (14 years old, non-verbal) went in and said very clearly the first sentence of his life. He looked at his dad and said, “I want to eat chips.” (parent of a study participant)
“This work is new and this type of clinical trial is expensive,” (Dr Naviaux) said. “We did not have enough funding to do a larger study. And even with the funding we were able to raise, we had to go $500,000 in debt to complete the trial.”
Naviaux R.K, Curtis B., Li K., et al. (2017) Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. doi:10.1002/acn3.424.
Cheng N., Rho J.M., & Masino S.A. (2017) Metabolic Dysfunction Underlying Autism Spectrum Disorder and Potential Treatment Approaches. Front Mol Neurosci. Feb 21;10:34. doi: 10.3389/fnmol.2017.00034.
Naviaux J.C., Schuchbauer M.A., Li K., et al. (2014) Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. Jun 17;4:e400. doi: 10.1038/tp.2014.33.
Naviaux J.C., Wang L., Li K., et al. (2015) Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Mol Autism. Jan 13;6:1. doi: 10.1186/2040-2392-6-1.
Naviaux R.K. (2014) Metabolic features of the cell danger response. Mitochondrion. May;16:7-17. doi: 10.1016/j.mito.2013.08.006.
“We must first recognise ASD as a whole body disorder” Autism, or Autism Spectrum Disorder ASD, is traditionally seen as the result of behavioural and neuropsychiatric dysfunction. However there is a strong evidence that various physical, or biomedical, problems can...
The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…
One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.
Several studies published in recent months investigated the effects of cannabis-based products for treating autism. Although the studies were open-label and relatively small in scale, the overall results were overwhelmingly positive, with statistically significant improvements in social communication, language, restrictive/repetitive and challenging behaviours.
Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome, Neurofibromatosis Type 1 suffer high rates of autism. Everolimus, an mTOR inhibitor with strong neuro-inflammation attenuating effects, reduces core autism symptoms in some children with TSC, epilepsy and autism…
Numerous medical conditions are significantly more prevalent in children and adults with autism, including allergy and/or immunologic, musculoskeletal, neurologic, psychiatric and gastrointestinal conditions. Early childhood health problems can be used to spot children at high risk of autism…
Double-blind randomized multicenter trial finds bumetanide ameliorates core symptoms of autism.A medical drug normally used to relieve fluid retention has been repurposed as a treatment for the core symptoms of autism. Following on from the promising results of their...
Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures. In a retrospective study a total...
Babies who are exposed to perinatal complicatios incl. asphyxia, preeclampsia, and meconium-stained amniotic fluid, are at increased risk of developing autism. The risk is especially high for babies exposed to complications both before and during birth.
Accumulating evidence suggests an association between immune dysfunction and pathogenesis of autism spectrum disorders in a large number of affected individuals. Findings from diverse fields of science and experimental animal studies point to close interconnectedness of the immune and the nervous systems
Autistic regression is a phenomenon where a previously normally developing child loses developmental milestones and previously acquired language and social skills, and regresses into autism. Symptoms such as fever, vomiting, incessant crying, irritability, changes in sleep patterns and emergence of motor abnormalities are frequently noted around the time of autistic regression…
Results of latest 12 month scientific study led by Prof Adams from Arizona State University suggest that a comprehensive nutritional protocol is both safe and effective at improving nutritional status, intellectual ability and autism symptoms in most individuals with autism